Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific has received United States (U.S.) Food and Drug Administration approval and CE Mark for the AngioJet ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.

30 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures.

11 Nov 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Acute Cardiovascular Care 2015 will highlight innovations and controversies in the field, guaranteeing great stories on topics relevant to the press.

18 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Novel radiopharmaceutical probe has potential to save lives of patients with ischemic stroke

A novel radiopharmaceutical probe developed at Massachusetts General Hospital has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism - conditions caused when important blood vessels are blocked by a clot that has traveled from another part of the body.

16 Sep 2015

Uninsured, Medicaid stroke victims experience worse medical outcomes than patients with private insurance

Stroke victims who use Medicaid or are uninsured were more likely to die, stay hospitalized longer and have worse medical outcomes than patients with private insurance, a study by University of Florida Health researchers has found.

14 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Prolonged television watching associated with twice the risk of fatal pulmonary embolism

Prolonged television watchers have a higher risk of fatal pulmonary embolism, a condition associated with long haul flights, reveals research presented at ESC Congress today by Mr Toru Shirakawa, public health research fellow in the Department of Social Medicine at Osaka University in Japan.

31 Aug 2015

ESC guideline adherent antithrombotic management improves outcomes in AF patients

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace.

31 Aug 2015

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Patient satisfaction a poor proxy for quality of care in elective cranial neurosurgery

Patient satisfaction is a very poor proxy for quality of care comparisons in elective cranial neurosurgery. Because deaths are rare events in elective cranial neurosurgery, reporting of surgeon or even department-specific mortality figures cannot differentiate a high or low level of the quality of care.

18 Aug 2015

Peripherally inserted central catheter use associated with lower-extremity DVT

Peripherally inserted central catheters (PICCs), a type of IV typically inserted in a vein in the arm, are frequently used by healthcare professionals to obtain long-term central venous access in hospitalized patients. While there are numerous benefits associated with PICCs, a potential complication is deep vein thrombosis (DVT), or blood clots, in upper limbs.

18 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

High-risk patients not receiving recommended treatment for blood clots

Venous thromboembolism (VTE), encompassing deep-vein thrombosis (DVT), or blood clots in leg veins, and pulmonary embolism (PE), or clots that travel to the lungs, is the most common cause of preventable death in hospital settings. While these clots can be prevented by an approach called VTE prophylaxis, and this reduces mortality by as much as 80%, VTE prophylaxis is not universally prescribed for high-risk patients.

10 Aug 2015

New UTMB study finds no association between testosterone therapy and blood clots in veins

A new study from The University of Texas Medical Branch at Galveston of more than 30,000 commercially insured men is the first large comparative analysis to show that there is no link between testosterone therapy and blood clots in veins. The study found that middle-aged and older men who receive testosterone therapy are not at increased risk of this illness.

21 Jul 2015

Alternative approach to treat fatal blood clots found to be more effective in patients

Potentially fatal blood clots account for thousands of emergency room visits each year and often those patients are admitted to the hospital, treated with an injectable anticoagulant and monitored for a few days.

17 Jul 2015